US3478019A - Halogenated cyclopropyl,cyclopropenyl and oxocyclopropenyl-1-hydroxy estratrienes and derivatives thereof - Google Patents

Halogenated cyclopropyl,cyclopropenyl and oxocyclopropenyl-1-hydroxy estratrienes and derivatives thereof Download PDF

Info

Publication number
US3478019A
US3478019A US668197A US3478019DA US3478019A US 3478019 A US3478019 A US 3478019A US 668197 A US668197 A US 668197A US 3478019D A US3478019D A US 3478019DA US 3478019 A US3478019 A US 3478019A
Authority
US
United States
Prior art keywords
triene
hydroxy
dimethoxy
acetoxyestra
sodium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US668197A
Inventor
John A Edwards
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Palo Alto LLC
Original Assignee
Roche Palo Alto LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Palo Alto LLC filed Critical Roche Palo Alto LLC
Application granted granted Critical
Publication of US3478019A publication Critical patent/US3478019A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J75/00—Processes for the preparation of steroids in general

Definitions

  • the present invention relates to novel steroids. More particularly, this invention relates tonovel estratrienes of the following Formula A:
  • R is selectedfrom the groups each of X and Y is chloro or fluoro;
  • each of R, R and 'R is hydroxy and the conventional hydrolyzable esters thereof, lower alkoxy, cyclopentyloxy, cyclohexyloxy, tetrahydrofuran-2-yloxy or tetrahydropyran-2'-yloxy;
  • R is hydrogen, methyl, ethyl or n-propyl
  • R is hydrogen, methyl, ethyl, chloro, "fluoro or trifluoromethyl.
  • hydrocarbon carboxylic acid defines both substituted and unsubstituted hydrocarbon carboxylic acids. These acids can be completely saturated or possess varying degrees of unsaturation (including aromatic), can be of straight chain, branched chain, or cyclic structure, and preferably contain from 1 to 12 carbon atoms.
  • Typical conventional hydrolyzable esters thus included within the scope of the term and the instant invention are acetate, propionate, butyrate, valerate, caproate, enanthate, caprylate, pelargonate, acrylate, undecenoate, phenoxyacetate, benzoate, phenylacetate, diphenylacetate, diethylacetate, trimethylacetate, t-butylacetate, trimethylhexanoate, methylneopentylacetate, cyclohexylacetate, cyclopentylpropionate, adamantoate, glycolate, methoxyacetate, hemisuccinate, hemiadipate, hemi-B,B-diemthylglutarate, acetoxyacetate, 2-chloro-4-nitrobenzoate, aminoacetate, diethylaminoacetate, piperidinoacetate, fl-chloro propionate, 'trichloroacetate, fi-chloro
  • lower alkoxy refers to a straight or branched chain alkoxy group having 1 to about 6 carbon atoms such as methoxy, ethoxy, and the like.
  • novel steroids provided by this invention are excellent estrogenic agents having a high degree of activity. They are useful in the treatment of the various conditions in which such agents are indicated, such as estrogen deficiencies, menopause, and the like. These compounds can also be used in veterinary medicine in the same manneras known estrogens and in the control and regulation of fertility. In addition, these novel steroids demonstrate anti-androgen activity. They can be administered either orally or percutaneously together with conventional pharmaceutical excipients at dosage rates of from about 3.0 ,ug. to about 2 mg./kg./day. However, dosages below or above this range can also be used, the most favorable dosage being dependent upon the purpose for which it is administered and the response thereto.
  • R is a dihalocyclopropenyl group
  • R is a dihalocyclopropenyl group
  • This process can be represented as follows using for simplicity and brevity only the applicable D ring of the steroid molecule:
  • R R R, X and Y are as defined above.
  • an estra-1,3,5(10)-triene of the general Formula A having a 17u-alkynyl group or 17a-halo-substituted alkynyl group eg ethynyl, l-propynyl, l-butynyl, chloroethynyl, fluoroethynyl, trifluoropropynyl, and the like
  • a dihalocarbene generated, for example, from alkali metal salts of haloacetic acid, e.g.
  • reaction is executed under anhydrous conditions in an inert organic solvent such as diglyme (diethyleneglycol dimethyl ether), triethyleneglycol dimethyl ether, or the like.
  • diglyme diethyleneglycol dimethyl ether
  • triethyleneglycol dimethyl ether triethyleneglycol dimethyl ether
  • R R R X and Y are as defined above.
  • This transformation can be accomplished by subjecting a steroid of Formula II to treatment with cold hydrochloric acid, aqueous formic acid, and the like for a few minutes, e.g. about 5-30 minutes or more, to furnish a 17a-cycl0- propenone of Formula IV.
  • the requisite starting material for the preparation of the compounds of the present invention is readily prepared from the corresponding 17-keto compound through conventional methods, e.g. treatment with acetylene and potassium t-butoxide, use of dichloroethylene and methyl lithium, use of alkynyl magnesium halides, and the like.
  • the starting materials having a 17a-alkenyl or halo-substituted alkenyl group are preferably obtained from the corresponding 17a-alkynyl or l7a-halo-substituted alkynyl compounds through controlled hydrogenation according to conventional procedures.
  • the resulting 17fi-hydroxy-l7a-alkenyl or -17x-alkyny1 starting materials can be converted to the corresponding 17B-acyloxy, 17fi-tetrahydropyranyloxy or 17B-tetrahydrofuranyloxy derivatives via conventional methods prior to practicing the process of this invention or can be subjected thereto directly and, if desired, esterified or etherified thereafter, preferably the former.
  • the substituent in the 1-position and the 3-position of the estratriene nucleus of the compounds of the present invention can be a hydroxy group or an etherified, e.g. methoxy, tetrahydropyranyloxy, etc., or esterified, e.g. acetoxy, benzoyloxy, etc., derivative thereof. These derivatives can be formed prior to the principal reaction of the present invention or can be formed thereafter via conventional methods, preferably prior thereto.
  • Suitable methods for the preparation of the starting compounds to obtain the compounds of the present in vention are set forth in, for example, US Patents 3,25 6,- 273, 3,262,949, 3,290,297, 3,300,484 and 3,318,925.
  • Starting material for compounds of the present invention having an 18-alkyl group can be obtained by treatment of an 18-alkylestra1,3,5(10)-triene with lead tetraacetate [Journal of the American Chemical Society, 80, 5683 (1958)] followed by treatment with trifluoroacetic anhydride [Chemische Berichte, 97 1926(l964)].
  • Example 1 To a refluxing solution of 6.2 g. of 1,3-dimethoxy-l7aethynylestra-1,3,5(l0)-trien-l7fl-ol l7-acetate in 50 ml. of anhydrous diglyme, there is added dropwise over a period of about minutes a heated (about 60 C.) solution of 20.72 g. of sodium chlorodifiuoroacetate in 50 ml. of anhydrous diglyme under nitrogen and with stirring. After all the sodium chlorodifluoroacetate is added, the reaction mixture is cooled and filtered. The filtrate is evaporated to dryness under reduced pressure.
  • Example 2 A suspension of 0.5 g. of 5% palladium-on-carbon catalyst in 50 ml. of methanol is hydrogenated for 30 minutes. A solution of 2 g. of 1,3dimethoxy-17ot-(2,2'- difiuorocyclopropenyl)-estra-1,3,5(10)-trien-l7 ⁇ 8 01 17- acetate in 200 ml. of methanol is added and hydrogenated with agitation until the uptake of hydrogen ceases.
  • Example 3 A mixture of 1 g. of 1,3-dimethoxy-17a-(2',2-difluorocyclopropenyl)-l7B-acetoxyestra-1,3,5(10)-triene and 25 ml. of aqueous formic acid is stirred at room temperature for 30 minutes. The mixture is then added to a 5% aqueous sodium bicarbonate solution which is then extracted with ethyl acetate. The ethyl acetate extracts are combined, washed, dried and evaporated to dryness to furnish 1,3-dimethoxy-17a-oxocyclopropenyl-l7/8-acetoxyestra-1,3,5(10)-triene which is recrystallized from acetone.
  • Example 4 To 144 mg. of sodium hydride in 8.5 ml. of anhydrous dimethyl sulfoxide, there is added under nitrogen 402 mg. of 1,3 dimethoxy-l'lu-(2',2'-difluorocyclopropenyl)-17 8- acetoxyestra-1,3,5(10)-triene in 2 ml. of anhydrous dimethyl sulfoxide and the mixture stirred for 30 minutes. To the mixture, there is then added 2 ml. of methyl iodide in 2 ml. of anhydrous dimethyl sulfoxide and the resulting mixture is stirred for 30 minutes. The reaction mixture is then filtered and the filtrate evaporated to dryness under reduced pressure.
  • Example 5 To 3.2 ml. of cold (0) concentrated hydrochloric acid is added with stirring, 0.1 g. of 1,3-dimethoxy-17ot-(2',2- difluorocyclopropenyl) 17/3 acetoxyestra 1,3,5(10)- triene. The mixture is stirred until the steroid is completely dissolved, then stirred for one additional minute, and finally poured into a mixture of aqueous sodium bicarbonate and ethyl acetate. The organic layer is separated and the aqueous phase extracted with ethyl acetate.
  • Example 2 By repeating the process of Example 1 using an equivalent amount of l,3-dimethoxy-17a-flu0roethynyl-17B- acetoxyestra-1,3,5(10)-triene in place of 1,3-dimethoxy- 17u-ethynyl-17fl-acetoxyestra-1,3,5(10)-triene as the starting material, there is obtained 1,3-dimethoxy-l7a-(2,2,3.' trifluorocyclopropenyl) -17B-acetoxyestra-l ,3,5 10)-triene.
  • Example 8 One gram of 1,3,l7fl-triacetoxy-17a-ethynylestra-l,3,5 (10)-triene is allowed to stand at room temperature for hours with 100 mg. of potassium bicarbonate in 10 ml. of water and 90 ml. of methanol. At the end of this time, the methanol is evaporated under reduced pressure and the residue is extracted with ethyl acetate and water. Evaporation of the ethyl acetate from these extracts yields 1,17 [3- diacetoxy 17oz ethynylestra 1,3,5 (10) trien- 3-ol which is collected by filtration and recrystallized from acetone hexane.
  • a solution of one chemical equivalent of the above prepared 3-hydroxy compound in 30 ml. of benzene is heated to reflux and about 2 ml. removed by distillation to eliminate moisture.
  • the mixture is cooled to room temperature and two chemical equivalents of sodium hydride are added, followed by the dropwise addition of two chemical equivalents of cyclopentyl bromide in 10 ml. of benzene over a period of 20 minutes.
  • a solution of 0.17 g. of potassium hydroxide in 0.2 ml. of water and 2.5 ml. of methanol is added over 30 minutes to a refluxing solution of 1 g. of 3-cyclopentyloxy- 1,17fl-diacetoxy-17a-(2',2-difluorocyclopropenyl) estra- 1,3,5 (10)-triene in 30 ml. of methanol under nitrogen.
  • the solution is refluxed for two hours, cooled, neutralized with acetic acid and concentrated under reduced pressure.
  • Example 9 The process of Example 1 is repeated with the exception that an equivalent amount of 17a-ethynyl-l,3-dicyclopentyloxy 17/3 acetoxyestra 1,3,5(l0) triene, 17aethynyl 1,3 diacetoxy 17B (tetrahydr0pyran-2- yloxy) estra 1,3,5(10) triene, 17oz ethynyl 17 3 (tetrahydropyran 2 yloxy) estra 1,3,5(10) triene 1,3-diol and Not-ethynylestra 1,3,5 (10)-triene 1,3,17/8- triol is used as the starting material in place of 1,3-dimethoxy-17a-ethynyl 17h acetoxyestra 1,3,5(10)- triene and the corresponding 17a-(2,2'-difluorocyclopropenyl) compound is obtained.
  • a solution of one chemical equivalent of 17a-ethynyl- 17fl-acetoxyestra-l,3,5(lO)-triene-1,3-diol in 30 ml. of benzene is heated to reflux and about 2 ml. removed by distillation to eliminate moisture.
  • the mixture is cooled to room temperature and two chemical equivalents of sodium hydride are added, followed by the dropwise addition of two chemical equivalents of cyclopentyl bromide in 10 ml. of benzene over a period of 20 minutes.
  • Example 10 One gram of 3 cyclopentyloxy 1,17/8 diacetoxy 17a (2',2' difluorocyclopropenyl) estra 1,3,5 (10) triene is allowed to stand at room temperature for 15 hours with 1 g. of potassium bicarbonate in 10 ml. of water and ml. of methanol. At the end of this time, the methanol is evaporated under reduced pressure and the residue is extracted with ethyl acetate and water.
  • Example 11 Two milliliters of dihydrofuran are added to a solution of 1 g. of 1,3-dimethoxy-17u-(2,2'-difluorocyclopropenyl)-estra-1,3,5(l0) trien 1713-01 in 15 ml. of benzene. About 1 ml. is removed by distillation to remove moisture and 0.4 g. of p-toluenesulfonic acid is added to the cooled solution. This mixture is allowed to stand at room temperature for four days, and is then washed with aqueous sodium carbonate solution and water, dried and evaporated.
  • R2 Hz wherein, R is selected from the groups /C X Y wherein R X and Y are as defined therein.
  • each of X and Y is fluoro, each of R and R is methoxy, R is acetoxy and R is hydrogen.
  • each of X and Y is fluoro, each of R and R is acetoxy, R is methoxy and R is hydrogen.
  • each of X and Y is fluoro, each of R and R is hydroxy, R is tetrahydropyran-2-yloxy and R is hydrogen.
  • each of X and Y is fiuoro, each of R and R is acetoxy, R is tetrahydropyran-2'-yloxy and R is hydrogen.
  • each of X and Y is fluoro, each of R and R is cyclopentyloxy, R is acetoxy and R is hydrogen.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Steroid Compounds (AREA)

Description

United States Patent ABSTRACT OFTHE DISCLOSURE 17m-dihalocyclopropyl-, dihalocyclopropenyh, and x0- cyclopropenyl-l-hydroxy-estratrienes useful as estragem'c agents.
The present invention relates to novel steroids. More particularly, this invention relates tonovel estratrienes of the following Formula A:
wherein, R is selectedfrom the groups each of X and Y is chloro or fluoro;
each of R, R and 'R is hydroxy and the conventional hydrolyzable esters thereof, lower alkoxy, cyclopentyloxy, cyclohexyloxy, tetrahydrofuran-2-yloxy or tetrahydropyran-2'-yloxy; p
R is hydrogen, methyl, ethyl or n-propyl; and
R is hydrogen, methyl, ethyl, chloro, "fluoro or trifluoromethyl.
.The term conventional hydrolyzable ester as used herein denotes those-hydrolyzable ester groupsconvcntionally employed in the steroid art, preferably, those de= rived'from hydrocarbon carboxylic acids or phosphoric acids and their salts. The term hydrocarbon carboxylic acid defines both substituted and unsubstituted hydrocarbon carboxylic acids. These acids can be completely saturated or possess varying degrees of unsaturation (including aromatic), can be of straight chain, branched chain, or cyclic structure, and preferably contain from 1 to 12 carbon atoms. In addition, they can be substituted by functional groups, for example, hydroxy, alkoxy containing up to six carbon atoms, acyloxy containing up to 12 carbon atoms, nitro, amino, halogeno, and the like, attached to the hydrocarbon backbone chain. Typical conventional hydrolyzable esters thus included within the scope of the term and the instant invention are acetate, propionate, butyrate, valerate, caproate, enanthate, caprylate, pelargonate, acrylate, undecenoate, phenoxyacetate, benzoate, phenylacetate, diphenylacetate, diethylacetate, trimethylacetate, t-butylacetate, trimethylhexanoate, methylneopentylacetate, cyclohexylacetate, cyclopentylpropionate, adamantoate, glycolate, methoxyacetate, hemisuccinate, hemiadipate, hemi-B,B-diemthylglutarate, acetoxyacetate, 2-chloro-4-nitrobenzoate, aminoacetate, diethylaminoacetate, piperidinoacetate, fl-chloro propionate, 'trichloroacetate, fi-chlorobutyrate, dihydrogen phosphate, dibenzyl phosphate, benzyl hydrogen phosp'hate, sodium benzyl phosphate, cyclohexylammonium benzyl phosphate, sodium phenyl phosphate, sodium ethyl phosphate, di p nitrobenzyl phosphate, sodium 0 methoxyphenyl phosphate, cyclohexylammonium p-cyanobenzyl phosphate, sodium phenacyl phosphate, benzyl ocarbomethoxy-phenyl phosphate, and the like.
The term lower alkoxy, as used herein, refers to a straight or branched chain alkoxy group having 1 to about 6 carbon atoms such as methoxy, ethoxy, and the like.
The novel steroids provided by this invention are excellent estrogenic agents having a high degree of activity. They are useful in the treatment of the various conditions in which such agents are indicated, such as estrogen deficiencies, menopause, and the like. These compounds can also be used in veterinary medicine in the same manneras known estrogens and in the control and regulation of fertility. In addition, these novel steroids demonstrate anti-androgen activity. They can be administered either orally or percutaneously together with conventional pharmaceutical excipients at dosage rates of from about 3.0 ,ug. to about 2 mg./kg./day. However, dosages below or above this range can also be used, the most favorable dosage being dependent upon the purpose for which it is administered and the response thereto.
The compounds of the present invention wherein R is a dihalocyclopropenyl group can be obtained by treating a l7u-alkyny1 estratriene of the general formula A with a dihalocarbene generating agent. This process can be represented as follows using for simplicity and brevity only the applicable D ring of the steroid molecule:
wherein, R R R, X and Y are as defined above.
In the practice of the foregoing transformation, an estra-1,3,5(10)-triene of the general Formula A having a 17u-alkynyl group or 17a-halo-substituted alkynyl group, eg ethynyl, l-propynyl, l-butynyl, chloroethynyl, fluoroethynyl, trifluoropropynyl, and the like, is treated with a dihalocarbene generated, for example, from alkali metal salts of haloacetic acid, e.g. sodium trichloroacetate, sodium chlorodifluoroacetate, and sodiumdichlorofiuoroacetate to yield the 17a-dihalocyclopropenyl derivatives of partial Formula II. The reaction is executed under anhydrous conditions in an inert organic solvent such as diglyme (diethyleneglycol dimethyl ether), triethyleneglycol dimethyl ether, or the like. The product forms directly and may be readily separated from the reaction mixture by conventional methods.
In the practice of the above process, in lieu of steroids of partial Formula I, there can be used estra-1,3,5'(10)- trienes having a l7a-alkenyl or halo-substituted alkenyl group in which case there are obtained novel 17a-dihalocyclopropyl steroids of the following partial Formula III:
' trienes of Formula II yields the novel l7a-cyclopropenones of the present invention which can be illustrated as follows:
wherein R R R X and Y are as defined above. This transformation can be accomplished by subjecting a steroid of Formula II to treatment with cold hydrochloric acid, aqueous formic acid, and the like for a few minutes, e.g. about 5-30 minutes or more, to furnish a 17a-cycl0- propenone of Formula IV.
The requisite starting material for the preparation of the compounds of the present invention is readily prepared from the corresponding 17-keto compound through conventional methods, e.g. treatment with acetylene and potassium t-butoxide, use of dichloroethylene and methyl lithium, use of alkynyl magnesium halides, and the like. The starting materials having a 17a-alkenyl or halo-substituted alkenyl group are preferably obtained from the corresponding 17a-alkynyl or l7a-halo-substituted alkynyl compounds through controlled hydrogenation according to conventional procedures.
The resulting 17fi-hydroxy-l7a-alkenyl or -17x-alkyny1 starting materials can be converted to the corresponding 17B-acyloxy, 17fi-tetrahydropyranyloxy or 17B-tetrahydrofuranyloxy derivatives via conventional methods prior to practicing the process of this invention or can be subjected thereto directly and, if desired, esterified or etherified thereafter, preferably the former.
The substituent in the 1-position and the 3-position of the estratriene nucleus of the compounds of the present invention can be a hydroxy group or an etherified, e.g. methoxy, tetrahydropyranyloxy, etc., or esterified, e.g. acetoxy, benzoyloxy, etc., derivative thereof. These derivatives can be formed prior to the principal reaction of the present invention or can be formed thereafter via conventional methods, preferably prior thereto.
Suitable methods for the preparation of the starting compounds to obtain the compounds of the present in vention are set forth in, for example, US Patents 3,25 6,- 273, 3,262,949, 3,290,297, 3,300,484 and 3,318,925. Starting material for compounds of the present invention having an 18-alkyl group can be obtained by treatment of an 18-alkylestra1,3,5(10)-triene with lead tetraacetate [Journal of the American Chemical Society, 80, 5683 (1958)] followed by treatment with trifluoroacetic anhydride [Chemische Berichte, 97 1926(l964)].
The following examples are provided to illustrate the practice of the present invention.
Example 1 To a refluxing solution of 6.2 g. of 1,3-dimethoxy-l7aethynylestra-1,3,5(l0)-trien-l7fl-ol l7-acetate in 50 ml. of anhydrous diglyme, there is added dropwise over a period of about minutes a heated (about 60 C.) solution of 20.72 g. of sodium chlorodifiuoroacetate in 50 ml. of anhydrous diglyme under nitrogen and with stirring. After all the sodium chlorodifluoroacetate is added, the reaction mixture is cooled and filtered. The filtrate is evaporated to dryness under reduced pressure. The residue is dissolved in hexane and chromatographed on 300 g. of Florisil (synthetic magnesium silicate) eluting with hexane:ether to furnish 1,3-dimethoxy-17a (232, djfiuorocyclopropenyl)-estra-1,3,5 (10)-trien-17}3-ol l7-acetate which is recrystallized from methanol.
Example 2 A suspension of 0.5 g. of 5% palladium-on-carbon catalyst in 50 ml. of methanol is hydrogenated for 30 minutes. A solution of 2 g. of 1,3dimethoxy-17ot-(2,2'- difiuorocyclopropenyl)-estra-1,3,5(10)-trien-l7}8 01 17- acetate in 200 ml. of methanol is added and hydrogenated with agitation until the uptake of hydrogen ceases. ,The catalyst is removed by filtration and the filtrate is evaporated to yield 1,3-dimethoxy-17a-(2',2-difluorocyclopropyl)-estra-1,3,5(10)-trien-l7;8-ol 17-acetate which can be recrystallized from methylene chloride:hexane for further purification.
Example 3 A mixture of 1 g. of 1,3-dimethoxy-17a-(2',2-difluorocyclopropenyl)-l7B-acetoxyestra-1,3,5(10)-triene and 25 ml. of aqueous formic acid is stirred at room temperature for 30 minutes. The mixture is then added to a 5% aqueous sodium bicarbonate solution which is then extracted with ethyl acetate. The ethyl acetate extracts are combined, washed, dried and evaporated to dryness to furnish 1,3-dimethoxy-17a-oxocyclopropenyl-l7/8-acetoxyestra-1,3,5(10)-triene which is recrystallized from acetone.
Example 4 To 144 mg. of sodium hydride in 8.5 ml. of anhydrous dimethyl sulfoxide, there is added under nitrogen 402 mg. of 1,3 dimethoxy-l'lu-(2',2'-difluorocyclopropenyl)-17 8- acetoxyestra-1,3,5(10)-triene in 2 ml. of anhydrous dimethyl sulfoxide and the mixture stirred for 30 minutes. To the mixture, there is then added 2 ml. of methyl iodide in 2 ml. of anhydrous dimethyl sulfoxide and the resulting mixture is stirred for 30 minutes. The reaction mixture is then filtered and the filtrate evaporated to dryness under reduced pressure. The residue is dissolved in ether and filtered. The filtrate is evaporated to dryness to give a residue which is chromatographed on Florisil eluting with hexane:ether to give 1,3-dimethoxy-17u-(2',2-difluoro-3'- methylcyclopropenyl) 17/3 acetoxyestra 1,3,5(l0)- triene and then eluting with ethylacetate to give 1,3-dimethoxy 17a (2' oxo 3' methylcyclopropenyD- 17 B-acetoxyestra- 1,3,5 10 -triene.
Example 5 To 3.2 ml. of cold (0) concentrated hydrochloric acid is added with stirring, 0.1 g. of 1,3-dimethoxy-17ot-(2',2- difluorocyclopropenyl) 17/3 acetoxyestra 1,3,5(10)- triene. The mixture is stirred until the steroid is completely dissolved, then stirred for one additional minute, and finally poured into a mixture of aqueous sodium bicarbonate and ethyl acetate. The organic layer is separated and the aqueous phase extracted with ethyl acetate. The combined organic solutions are then washed with water to neutrality, dried over sodium sulfate and evaporated to dryness to yield 1,3-dimethoxy-17u-oxocyclopropenyl-17,8- acetoxyestra-1,3,5(10)-triene which may be further purified through recrystallization from methanol.
Example 6 1,3,17p triacetoxy-17u-ethynylestra-1, 3 ,5 )-triene,
v17fl-acetoxy-17ot-ethynylestra-1,3,5 l0)-triene-1,3-diol,
17,3-acetoxy-l7u-ethynyl- 1 ,3-di(tetrahydropyran-2'- yloxy) -estra-l,3,5 10) -triene,
. 1 ,3-diacetoxy-17a-ethynyl-175-methoxyestra-1,3,5 10
triene, v 1,3-dicyclopentyloxy-17u-ethynyl-17,8-acetoxyestra- 1,3,5 10)-triene, 3-cyclopentyloxy-17fi-acetoxy-17a-ethynylestra-l ,3,5 10) trieri-l-ol, 3 -cyclopentyloxy-1,17/3-diacetoxy-Hot-ethynylestra- 1,3,5 10) -triene,
I 1,3,17,6-triacetoxy-17a-ethynyl-l8-methylestra-1,3,5 (10)- triene, and 1,3,17fl-trimethoxy-17a-ethynylestra-l,3,5 10)-triene fluoroacetate in place of sodium chlorodifluoroacetate, there is obtained 1,3-dimethoxy-17a-(2'-chloro-2'-fluorocyclopropenyl) -17fl-acetoxyestra-1,3,5 (10) triene which can be subjected to the process of Example 2 to obtain 1,3 dimethoxy. 17oz (2 chloro 2' fluorocyclopropyl)-17B-acetoxyestra-1,3,5(10)-triene.
By repeating the process of Example 1 using an equivalent amount of l,3-dimethoxy-17a-flu0roethynyl-17B- acetoxyestra-1,3,5(10)-triene in place of 1,3-dimethoxy- 17u-ethynyl-17fl-acetoxyestra-1,3,5(10)-triene as the starting material, there is obtained 1,3-dimethoxy-l7a-(2,2,3.' trifluorocyclopropenyl) -17B-acetoxyestra-l ,3,5 10)-triene.
Example 8 One gram of 1,3,l7fl-triacetoxy-17a-ethynylestra-l,3,5 (10)-triene is allowed to stand at room temperature for hours with 100 mg. of potassium bicarbonate in 10 ml. of water and 90 ml. of methanol. At the end of this time, the methanol is evaporated under reduced pressure and the residue is extracted with ethyl acetate and water. Evaporation of the ethyl acetate from these extracts yields 1,17 [3- diacetoxy 17oz ethynylestra 1,3,5 (10) trien- 3-ol which is collected by filtration and recrystallized from acetone hexane.
A solution of one chemical equivalent of the above prepared 3-hydroxy compound in 30 ml. of benzene is heated to reflux and about 2 ml. removed by distillation to eliminate moisture. The mixture is cooled to room temperature and two chemical equivalents of sodium hydride are added, followed by the dropwise addition of two chemical equivalents of cyclopentyl bromide in 10 ml. of benzene over a period of 20 minutes. The mixture is allowed to reflux for 20 hours after which time the precipitate of sodium bromide is removed by filtration and the organic phase dried and evaporated to yield 3-cyclopentyloxy- 1, l7/3-diacetoxy- 17a-ethynylestra- 1,3 ,5 (10)-triene which is further purified upon recrystallization from pentane.
The above prepared compound is then subjected to the process of Example 1 and there is obtained 3-cyclopenty1 oxy 1,17 8 diacetoxy 17oz (2',2' difluorocyclopropeny1)-estra-1,3,5 10 -triene.
A solution of 0.17 g. of potassium hydroxide in 0.2 ml. of water and 2.5 ml. of methanol is added over 30 minutes to a refluxing solution of 1 g. of 3-cyclopentyloxy- 1,17fl-diacetoxy-17a-(2',2-difluorocyclopropenyl) estra- 1,3,5 (10)-triene in 30 ml. of methanol under nitrogen. The solution is refluxed for two hours, cooled, neutralized with acetic acid and concentrated under reduced pressure. After the addition of water, the solid which forms is collected by filtration and dried to yield 3-cyclopentyloxy- 17a (2',2' difluorocyclopropenyl) estra 1,3,5(10)- triene-1,17,8-diol which is recrystallized from acetone: hexane.
Example 9 The process of Example 1 is repeated with the exception that an equivalent amount of 17a-ethynyl-l,3-dicyclopentyloxy 17/3 acetoxyestra 1,3,5(l0) triene, 17aethynyl 1,3 diacetoxy 17B (tetrahydr0pyran-2- yloxy) estra 1,3,5(10) triene, 17oz ethynyl 17 3 (tetrahydropyran 2 yloxy) estra 1,3,5(10) triene 1,3-diol and Not-ethynylestra 1,3,5 (10)-triene 1,3,17/8- triol is used as the starting material in place of 1,3-dimethoxy-17a-ethynyl 17h acetoxyestra 1,3,5(10)- triene and the corresponding 17a-(2,2'-difluorocyclopropenyl) compound is obtained.
A solution of one chemical equivalent of 17a-ethynyl- 17fl-acetoxyestra-l,3,5(lO)-triene-1,3-diol in 30 ml. of benzene is heated to reflux and about 2 ml. removed by distillation to eliminate moisture. The mixture is cooled to room temperature and two chemical equivalents of sodium hydride are added, followed by the dropwise addition of two chemical equivalents of cyclopentyl bromide in 10 ml. of benzene over a period of 20 minutes. The mixture is allowed to reflux for 20 hours after which time the precipitate of sodium bromide is removed by filtration and the organic phase dried and evaporated to yield 1,3 dicyclopentyloxy 17oz ethynyl 17 8 -acetoxyestra-1,3,5(10)-triene which is further purified upon recrystallization from pentane.
Example 10 One gram of 3 cyclopentyloxy 1,17/8 diacetoxy 17a (2',2' difluorocyclopropenyl) estra 1,3,5 (10) triene is allowed to stand at room temperature for 15 hours with 1 g. of potassium bicarbonate in 10 ml. of water and ml. of methanol. At the end of this time, the methanol is evaporated under reduced pressure and the residue is extracted with ethyl acetate and water. Evaporation of the ethyl acetate from these extracts yields 3 cyclopentyloxy -17/8 acetoxy 17oz (2,2 difluorocyclopropenyl) estra 1,3,5(10) trien 1 01 which is collected by filtration and recrystallized from acetone: hexane.
Example 11 Two milliliters of dihydrofuran are added to a solution of 1 g. of 1,3-dimethoxy-17u-(2,2'-difluorocyclopropenyl)-estra-1,3,5(l0) trien 1713-01 in 15 ml. of benzene. About 1 ml. is removed by distillation to remove moisture and 0.4 g. of p-toluenesulfonic acid is added to the cooled solution. This mixture is allowed to stand at room temperature for four days, and is then washed with aqueous sodium carbonate solution and water, dried and evaporated. The residue is chromatographed on neutral alumina, eluting with hexane, to yield l,3-dimethoxy-l7u- (2',2'-difluorocyclopropenyl) 17B (tetrahydrofuran-2'- yloxy)-estra-l,3,5(10)-triene which is recrystallized from pentane.
Use of this process with the other free hydroxy compounds of the present invention will similarly yield the corresponding (tetrahydrofuran-Z-yloxy) derivatives. Likewise, through the use of dihydropyran in place of dihydrofuran, the corresponding tetrahydropyran 2' yl ethers are obtained.
7 What is claimed is: 1. A compound selected from those of the following formula:
R2 Hz wherein, R is selected from the groups /C X Y wherein R X and Y are as defined therein.
3. A compound according to claim 2 wherein each of X and Y is fluoro.
4. A compound according to claim 2 wherein each of X and Y is fiuoro and each of R, R and R is acetoxy and R is hydrogen.
5. A compound according to claim 2 wherein each of X and Y is fluoro, each of R and R is methoxy, R is acetoxy and R is hydrogen.
6. A compound according to claim 2 wherein each of X and Y is fluoro, each of R, R and R is hydroxy and R is hydrogen.
7. A compound according to claim 2 wherein each .of X and Y is fluoro, each of R and R is hydroxy, R is acetoxy and R is hydrogen.
8. A compound according to claim 2 wherein each of X and Y is fluoro, each of R and R is acetoxy, R is methoxy and R is hydrogen.
9. A compound according to claim 2 wherein each of X and Y is fluoro, each of R and R is hydroxy, R is tetrahydropyran-2-yloxy and R is hydrogen.
10. A compound according to claim 2 wherein each of X and Y is fiuoro, each of R and R is acetoxy, R is tetrahydropyran-2'-yloxy and R is hydrogen.
11. A compound according to claim 2 wherein each of X and Y is fluoro, each of R and R is cyclopentyloxy, R is acetoxy and R is hydrogen.
12. A compound according to claim 2 wherein each of X and Y is fiuoro, R is cyclopentyloxy, R is hydroxy, R is acetoxy and R is hydrogen.
13. A compound according to claim 2 wherein each of X and Y is fiuoro, R is cyclopentyloxy, each of R and R is acetoxy and R is hydrogen.
References Cited UNITED STATES PATENTS 2,861,086 11/1958 Jiu 260-3974 3,385,871 5/1968 Edwards et a1 260397.4 3,392,165 7/1968 Edwards et a1. 260239.55
LEWIS GOTTS, Primary Examiner ETHEL G. LOVE, Assistant Examiner US. Cl. X.R.
UNITED STATES PATENT OFFICE CERTIFICATE OF CORRECTION Patent No. 478,019 Dated November 11, 1969 Inventor(s) John A Edwards It is certified that error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown below:
Column 7, in Claim 1, lines 16 through 25, cancel the material in brackets depicted as follows:
C -c C R C X X SiGNED AND L SEALED JuN231970 fi Amt:
A g officer Commissioner of Patent!
US668197A 1967-09-15 1967-09-15 Halogenated cyclopropyl,cyclopropenyl and oxocyclopropenyl-1-hydroxy estratrienes and derivatives thereof Expired - Lifetime US3478019A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US66819767A 1967-09-15 1967-09-15

Publications (1)

Publication Number Publication Date
US3478019A true US3478019A (en) 1969-11-11

Family

ID=24681390

Family Applications (1)

Application Number Title Priority Date Filing Date
US668197A Expired - Lifetime US3478019A (en) 1967-09-15 1967-09-15 Halogenated cyclopropyl,cyclopropenyl and oxocyclopropenyl-1-hydroxy estratrienes and derivatives thereof

Country Status (1)

Country Link
US (1) US3478019A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3682984A (en) * 1970-01-19 1972-08-08 Syntex Corp 17{60 -(2,3-methylene-prop-1-en-1 yl)-steroids and 17{60 -(2,3-monohalomethylene and 2,3-dihalomethylene) derivatives thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2861086A (en) * 1957-12-27 1958-11-18 Searle & Co 17-oxygenated estra-1, 3, 5(10)-triene-1, 3-diols, and the corresponding esters and ethers
US3385871A (en) * 1965-12-15 1968-05-28 Syntex Corp Halogenated cyclopropyl and cyclopropenyl estratrienes and process for their preparation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2861086A (en) * 1957-12-27 1958-11-18 Searle & Co 17-oxygenated estra-1, 3, 5(10)-triene-1, 3-diols, and the corresponding esters and ethers
US3385871A (en) * 1965-12-15 1968-05-28 Syntex Corp Halogenated cyclopropyl and cyclopropenyl estratrienes and process for their preparation
US3392165A (en) * 1965-12-15 1968-07-09 Syntex Corp Estra-1, 3, 5-(10)-trienes substituted at the 17alpha-position with a propadienyl or substituted propadienyl radical

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3682984A (en) * 1970-01-19 1972-08-08 Syntex Corp 17{60 -(2,3-methylene-prop-1-en-1 yl)-steroids and 17{60 -(2,3-monohalomethylene and 2,3-dihalomethylene) derivatives thereof

Similar Documents

Publication Publication Date Title
US3492321A (en) Cyclopropenyl estra, -1,3,5(10)-trienes
US3166577A (en) 1, 2-dimethyl estrogens and intermediates used in the production thereof
US3414592A (en) 6, 7-halomethylene androstanes and estranes and processes for their preparation
US3392165A (en) Estra-1, 3, 5-(10)-trienes substituted at the 17alpha-position with a propadienyl or substituted propadienyl radical
US3392166A (en) Androst-4-enes and estr-4-enes having a 17alpha-diethylenically unsaturated side chain
US3492318A (en) Cyclopropenyl androstanes
US3478019A (en) Halogenated cyclopropyl,cyclopropenyl and oxocyclopropenyl-1-hydroxy estratrienes and derivatives thereof
US3256273A (en) 17beta-tetrahydropyranyl derivatives of estradiols
US3481957A (en) Novel androstane and 19-norandrostane steroidal esters and their preparation
US3239542A (en) 19 nor-deta2-androstene-17beta-ol and the esters thereof
US3101356A (en) 19-halo androstenes
US3520882A (en) 5',6'-dihydro-2h-pyran-4'-yl ethers of estrogenic steroids
US3055920A (en) 2-hydroxymethyl-delta2-androsten derivatives and process
US3455972A (en) Novel 6-spiro-(6',6'-dihalocyclopropyl) steroids
US3118915A (en) 2alpha-lower alkyl dihydro testosterone and derivatives thereof
US3435056A (en) Halogenated cyclopropyl and cyclopropenyl steroids and process for their preparation
US3484465A (en) Bicyclo(2.2.2)octane - 1-carboxylate carbonate esters of estrogenic steroids
US3167547A (en) 17-tetrahydropyranyl ethers of 19-nor, 3-keto androstanes
US3082223A (en) 2-methylene-androstanes
US3214447A (en) 2alpha-methyl-11-oxygenated androstanes and intermediates therefor
US3210389A (en) 19-halo-delta-4-10alpha-androsten-17beta-ol-3-one
US3565918A (en) 7alpha-difluoromethyl-a-nor-b-homo steroids and their preparation
US3148186A (en) Derivatives of 2-formyl-2-androstenes and pregnenes
US3520881A (en) Lower alkoxytetrahydropyranyl ethers of estrogenic steroids
US3188326A (en) 2-methyl derivatives of delta2-androsten-17beta-ol